Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day

By sjmartinez • March 3, 2023

Taylor MH, Leboulleux S, Panaseykin Y, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D, Sherif B, Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Med. 2023 Feb;12(4):4332-4342. doi: 10.1002/cam4.5308. Epub 2022 Dec 4. PMID: 36464853; PMCID: PMC9972135.

Tags: dose intensity, Endocrinology, Harbor UCLA, HRQoL, kinase inhibitor, lenvatinib, Quality of Life, radioiodine-refractory differentiated thyroid cancer

Population-Level Teleretinal Screening Bulk Orders to Improve Diabetic Retinopathy Screening Rates: A Randomized Quality Improvement Trial

Takimoto SW, Freeby M, Han M, Vangala S, Fujimoto J, Dermenchyan A, Lambrechts S. Population-Level Teleretinal Screening Bulk Orders to Improve Diabetic Retinopathy Screening Rates:[...]

Body composition changes during cardiac rehabilitation and long-term cardiovascular outcomes in patients with coronary artery disease

Kumar A, Van C, Shahrvini T, Srikanthan P, Horwich TB. Body composition changes during cardiac rehabilitation and long-term cardiovascular outcomes in patients with coronary artery[...]

Considerations and best practices for respirometry

Ball AB, Stiles L, Divakaruni AS. Considerations and best practices for respirometry. Cell Metab. 2026 Jun 2;38(6):1093-1096. doi: 10.1016/j.cmet.2026.05.001. PMID: 42229405.